Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

H. G. Katz, Matthew; Shi, Qian; Meyers, Jeff; M. Herman, Joseph; Chuong, Michael; M. Wolpin, Brian; Ahmad, Syed; Marsh, Robert; Schwartz, Larry; Behr, Spencer; L. Frankel, Wendy; Collisson, Eric; Leenstra, James; M. Williams, Terence; Vaccaro, Gina; Venook, Alan; A. Meyerhardt, Jeffrey; M. O’Reilly, Eileen

doi:10.1001/jamaoncol.2022.2319

Public

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

Shared by NobleBlocks on Sep 1, 2022 • 12:00 AM UTC

Authors:

Matthew H. G. Katz

Qian Shi

Jeff Meyers

Abstract

Importance National guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear. Objective To compare treatment with neoadjuvant modified FOLFIRINOX (mFOLFIRINOX) with or without hypofractionated ra...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!